Analysis of Real-World Data on Postremission Therapy for Acute Myeloid Leukemia with Intermediate Risk Cytogenetics in First Complete Remission

Curative treatment of acute myeloid leukemia (AML) is based on one or two cycles of remission induction chemotherapy followed by consolidation chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in those patients who enter complete remission (CR).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia. The study cohort inc...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Low EFS and OS rates were found for AML patients in the AYA group. To improve survival rates, intensified chemotherapy regimens and early hematopoietic stem cell transplantation are needed. Micro-Abstract Hispanic patients aged < 40 years with a diagnosis of acute myeloid leukemia (AML) during 2003 to 2016 in Northeast Mexico were evaluated. The group included 46 children and 88 adolescents and young adults (AYAs) aged 15 to 39 years. A greater overall response rate was found in the children (87.2% vs. 69% in AYAs). Low event-free and overall survival rates for AYA patients with AML were documented.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML. Micro-Abstract Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic h...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our data seem to confirm the value of FLAG-Ida in this setting and might suggest its best usage as bridge therapy for patients awaiting allotransplantation. Micro-Abstract Allotransplant is crucial for improving survival in refractory/first relapsed AML patients. An overall response was achieved in 48 patients (44% of the whole group) with FLAG-Ida chemotherapy approach. 24 of 48 responders underwent allotransplantation obtaining a median OS of 60 months.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion A single-institutional retrospective analysis found no significant differences in outcomes using GCLAC or CLAG for rrAML patients, though formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was higher than CLAG which should be considered when evaluating salvage chemotherapy options.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic hematopoietic cell transplant. Overall, CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel J. Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare condition, most often associated with acute myeloid leukemia (AML), although in some rare cases it may present in nonleukemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site, leading to very varied clinical presentations. Diagnosis is challenging and relies on a high ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumour of immature granulytic cells. It is a rare condition, most often associated with acute myeloid leukaemia although in some rare cases it may present in non-leukaemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with Acute Myeloid Leukemia (AML) access to allo-SCT and mortality has decreased1. However, 30-40% of patients relapse, outcome after post-transplant relapse is poor and most patients do not benefit from salvage chemotherapy. Approximately one third of these patients harbor FLT3 internal tandem duplication (FLT3-ITD) which is associated with sensitivity to several Tyrosine Kinase Inhibitors (TKI). Sorafenib is a multikinase inhibitor targeting FLT3 and the Raf/ERK/MAP kinase pathway with single agent clinical activity in FLT3 mutated ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Study | Transplants